目次

Table of Contents

Executive Summary
Market Overview

Market Landscape
Market ecosystem
Value chain analysis

Market Sizing
Market definition
Market segment analysis
Market size 2020
Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
Five Forces Summary
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

Market Segmentation by Product
Market segments
Comparison by Product
Calcium channel alpha-2-delta ligand - Market size and forecast 2020-2025
SNRIs and TCAs - Market size and forecast 2020-2025
Market opportunity by Product

Customer landscape
Overview

Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
ROW - Market size and forecast 2020-2025
Key leading countries
Market opportunity By Geographical Landscape

Drivers, Challenges, and Trends
Market drivers
Market challenges
Market trends

Vendor Landscape
Overview
Landscape disruption
Competitive landscape

Vendor Analysis
Vendors covered
Market positioning of vendors
Alnylam Pharmaceuticals Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Daiichi Sankyo Co. Ltd.
Eli Lilly and Co.
Grunenthal GmbH
Johnson and Johnson Inc.
NeuroBo Pharmaceuticals Inc.
Novartis AG

Appendix
Scope of the report
Currency conversion rates for US$
Research Methodology
List of abbreviations

1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2020 - 2025 ($ million)
13: Global market: Year-over-year growth 2020 - 2025 (%)
14: Five forces analysis 2020 & 2025
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2020
21: Product - Market share 2020-2025 (%)
22: Comparison by Product
23: Calcium channel alpha-2-delta ligand - Market size and forecast 2020-2025 ($ million)
24: Calcium channel alpha-2-delta ligand - Year-over-year growth 2020-2025 (%)
25: SNRIs and TCAs - Market size and forecast 2020-2025 ($ million)
26: SNRIs and TCAs - Year-over-year growth 2020-2025 (%)
27: Others - Market size and forecast 2020-2025 ($ million)
28: Others - Year-over-year growth 2020-2025 (%)
29: Market opportunity by Product
30: Customer landscape
31: Market share By Geographical Landscape 2020-2025 (%)
32: Geographic comparison
33: North America - Market size and forecast 2020-2025 ($ million)
34: North America - Year-over-year growth 2020-2025 (%)
35: Europe - Market size and forecast 2020-2025 ($ million)
36: Europe - Year-over-year growth 2020-2025 (%)
37: Asia - Market size and forecast 2020-2025 ($ million)
38: Asia - Year-over-year growth 2020-2025 (%)
39: ROW - Market size and forecast 2020-2025 ($ million)
40: ROW - Year-over-year growth 2020-2025 (%)
41: Key leading countries
42: Market opportunity By Geographical Landscape ($ million)
43: Impact of drivers and challenges
44: Vendor landscape
45: Landscape disruption
46: Industry risks
47: Vendors covered
48: Market positioning of vendors
49: Alnylam Pharmaceuticals Inc. - Overview
50: Alnylam Pharmaceuticals Inc. - Product and service
51: Alnylam Pharmaceuticals Inc. - Key offerings
52: Alnylam Pharmaceuticals Inc. - Key customers
53: Alnylam Pharmaceuticals Inc. - Segment focus
54: Astellas Pharma Inc. - Overview
55: Astellas Pharma Inc. - Product and service
56: Astellas Pharma Inc. - Key offerings
57: Astellas Pharma Inc. - Key customers
58: Astellas Pharma Inc. - Segment focus
59: AstraZeneca Plc - Overview
60: AstraZeneca Plc - Product and service
61: AstraZeneca Plc - Key offerings
62: AstraZeneca Plc - Key customers
63: AstraZeneca Plc - Segment focus
64: Daiichi Sankyo Co. Ltd. - Overview
65: Daiichi Sankyo Co. Ltd. - Business segments
66: Daiichi Sankyo Co. Ltd. - Key offerings
67: Daiichi Sankyo Co. Ltd. - Key customers
68: Daiichi Sankyo Co. Ltd. - Segment focus
69: Eli Lilly and Co. - Overview
70: Eli Lilly and Co. - Business segments
71: Eli Lilly and Co. - Key offerings
72: Eli Lilly and Co. - Key customers
73: Eli Lilly and Co. - Segment focus
74: Grunenthal GmbH - Overview
75: Grunenthal GmbH - Product and service
76: Grunenthal GmbH - Key offerings
77: Grunenthal GmbH - Key customers
78: Grunenthal GmbH - Segment focus
79: Johnson and Johnson Inc. - Overview
80: Johnson and Johnson Inc. - Business segments
81: Johnson and Johnson Inc. - Key offerings
82: Johnson and Johnson Inc. - Key customers
83: Johnson and Johnson Inc. - Segment focus
84: NeuroBo Pharmaceuticals Inc. - Overview
85: NeuroBo Pharmaceuticals Inc. - Product and service
86: NeuroBo Pharmaceuticals Inc. - Key offerings
87: NeuroBo Pharmaceuticals Inc. - Key customers
88: NeuroBo Pharmaceuticals Inc. - Segment focus
89: Novartis AG - Overview
90: Novartis AG - Business segments
91: Novartis AG - Key offerings
92: Novartis AG - Key customers
93: Novartis AG - Segment focus
94: Pfizer Inc. - Overview
95: Pfizer Inc. - Business segments
96: Pfizer Inc. - Key offerings
97: Pfizer Inc. - Key customers
98: Pfizer Inc. - Segment focus
99: Currency conversion rates for US$
100: Research Methodology
101: Validation techniques employed for market sizing
102: Information sources
103: List of abbreviations